Tags

Type your tag names separated by a space and hit enter

New concepts in the treatment of Parkinson's disease.
Am Fam Physician. 1990 Feb; 41(2):574-84.AF

Abstract

Carbidopa/levodopa remains the most potent drug for the treatment of Parkinson's disease. Several newer medications may help stabilize and improve such problems as fluctuating responses to the medication, drug-induced dyskinesias and refractory symptoms. Patients with fluctuating responses that do not respond to adjustments in the carbidopa/levodopa dose may benefit from the addition of a direct-acting dopamine agonist, such as pergolide or bromocriptine. While carbidopa/levodopa and the direct-acting dopamine agonists have a proven track record as symptomatic treatment, they probably do not alter the pathologic process underlying this progressive condition. On the other hand, two studies have shown that selegiline might slow the progression of Parkinson's disease, independent of any direct effects on symptoms.

Authors+Show Affiliations

Mayo Medical School, Rochester, Minnesota.No affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

1967895

Citation

Ahlskog, J E., and J M. Wilkinson. "New Concepts in the Treatment of Parkinson's Disease." American Family Physician, vol. 41, no. 2, 1990, pp. 574-84.
Ahlskog JE, Wilkinson JM. New concepts in the treatment of Parkinson's disease. Am Fam Physician. 1990;41(2):574-84.
Ahlskog, J. E., & Wilkinson, J. M. (1990). New concepts in the treatment of Parkinson's disease. American Family Physician, 41(2), 574-84.
Ahlskog JE, Wilkinson JM. New Concepts in the Treatment of Parkinson's Disease. Am Fam Physician. 1990;41(2):574-84. PubMed PMID: 1967895.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - New concepts in the treatment of Parkinson's disease. AU - Ahlskog,J E, AU - Wilkinson,J M, PY - 1990/2/1/pubmed PY - 1990/2/1/medline PY - 1990/2/1/entrez SP - 574 EP - 84 JF - American family physician JO - Am Fam Physician VL - 41 IS - 2 N2 - Carbidopa/levodopa remains the most potent drug for the treatment of Parkinson's disease. Several newer medications may help stabilize and improve such problems as fluctuating responses to the medication, drug-induced dyskinesias and refractory symptoms. Patients with fluctuating responses that do not respond to adjustments in the carbidopa/levodopa dose may benefit from the addition of a direct-acting dopamine agonist, such as pergolide or bromocriptine. While carbidopa/levodopa and the direct-acting dopamine agonists have a proven track record as symptomatic treatment, they probably do not alter the pathologic process underlying this progressive condition. On the other hand, two studies have shown that selegiline might slow the progression of Parkinson's disease, independent of any direct effects on symptoms. SN - 0002-838X UR - https://www.unboundmedicine.com/medline/citation/1967895/New_concepts_in_the_treatment_of_Parkinson's_disease_ L2 - https://medlineplus.gov/parkinsonsdisease.html DB - PRIME DP - Unbound Medicine ER -